Markets

Stock Alert: Co-Diagnostics Up 15% On COVID-19 Test Approval

(RTTNews) - Shares of Co-Diagnostics, Inc. (CODX) jumped 15% on Monday morning after the company announced it received FDA's emergency use authorization for its Covid-19 test.

CODX is currently trading at $27.49, up $3.49 or 14.55%, on the Nasdaq.

Co-Diagnostics said its partner, Clinical Reference Laboratory has FDA Emergency Use Authorization for CRL Rapid Response, a saliva-based COVID-19 test that can be self-administered at home, work or any other setting and then tested using Co-Diagnostics' patented CoPrimer technology.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

CODX

Latest Markets Videos

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Learn More